At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Temsirolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of CCI-779 (Temsirolimus) in Patients With Locally Advanced or Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Temsirolimus for Recurrent Breast Carcinoma and 5 related conditions. Completed, enrolled 31 participants across 2 sites.
Detailed Summary
This phase II trial studies how well temsirolimus works in treating patients with breast cancer that has spread to other places in the body. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedSep 2006
Primary CompletionJun 2008
Study CompletionDec 2019
TodayJul 2026
First PostedSep 15, 2006
Enrollment StartJul 11, 2006
Primary CompletionJun 12, 2008
Study CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.8 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Temsirolimusdrug
Given IV